---
document_datetime: 2025-12-02 06:25:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/samsca.html
document_name: samsca.html
version: success
processing_time: 0.0984291
conversion_datetime: 2025-12-26 17:13:14.899453
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Samsca

[RSS](/en/individual-human-medicine.xml/66463)

##### Authorised

This medicine is authorised for use in the European Union

tolvaptan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Samsca is a medicine for treating abnormally low levels of sodium in the blood in adults with a condition called 'syndrome of inappropriate antidiuretic hormone secretion' (SIADH).

In SIADH, an excessive amount of the hormone vasopressin makes the patient produce less urine and thereby retain more water in the body, which dilutes the concentration of sodium in the blood.

Samsca contains the active substance tolvaptan.

Expand section

Collapse section

## How is Samsca used?

Samsca is available as tablets (7.5, 15 and 30 mg). The starting dose is 15 mg once a day. This may be increased to a maximum of 60 mg once a day to achieve an appropriate level of blood sodium and blood volume. A dose of 7.5 mg once a day can be used for patients at risk of excessively quick rise in blood sodium.

The medicine can only be obtained with a prescription. Treatment with Samsca should be started in hospital so that healthcare professionals can determine the most appropriate dose and monitor the patient's level of blood sodium and blood volume.

For more information about using Samsca, see the package leaflet or contact your doctor or pharmacist.

## How does Samsca work?

People with SIADH have an excessive amount of vasopressin, leading to decreased urine production and dilution of the blood. The active substance in Samsca, tolvaptan, is a 'vasopressin?2 receptor antagonist'. This means that it blocks one type of receptor (target) to which the hormone vasopressin normally attaches itself. By blocking this receptor, Samsca prevents vasopressin's effect. This increases urine production, decreasing the amount of water in the blood and increasing the blood sodium level.

## What benefits of Samsca have been shown in studies?

Two studies involving 424 adults showed that Samsca is effective at increasing sodium levels in patients with low levels caused by SIADH and other conditions such as liver and heart problems. However, Samsca was more effective in patients with SIADH than in those with liver or heart problems. Normal sodium levels are between 135 and 145 mmol/l.

In patients with SIADH, sodium levels, which were around 129 mmol/l at the start of treatment, rose by an average of 4.8 mmol/l by day 4 in those who took Samsca, compared with 0.2 mmol/l in those who took placebo (dummy treatment). By day 30, sodium had increased by an average of 7.4 mmol/l in patients who took Samsca, compared with 1.5 mmol/l in patients receiving placebo.

## What are the risks associated with Samsca?

The most common side effects with Samsca (which may affect more than 1 patient in 10) are thirst, nausea (feeling sick) and sodium levels rising too quickly. For the full list of side effects reported with Samsca, see the package leaflet.

Samsca must not be used in patients with anuria (an inability to pass urine), very low blood volume, low blood sodium levels with low blood volume, hypernatremia (abnormally high levels of sodium in the blood) or in patients who cannot perceive thirst. It must not be used in patients who are allergic to tolvaptan or medicines that are similar to tolvaptan, so-called benzazepines or their derivatives. Samsca must also not be used in women who are pregnant or breast-feeding. For the full list of restrictions, see the package leaflet.

## Why is Samsca authorised in the EU?

Samsca has been shown to be effective at increasing sodium levels, particularly in patients with SIADH. The only major safety concerns seen with this medicine came from animal studies suggesting it could be harmful to unborn babies. This medicine must therefore not be used in women who are pregnant or breastfeeding.

The European Medicines Agency concluded that Samsca's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Samsca?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Samsca have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Samsca are continuously monitored. Side effects reported with Samsca are carefully evaluated and any necessary action taken to protect patients.

## Other information about Samsca

Samsca received a marketing authorisation valid throughout the European Union on 3 August 2009.

Samsca : EPAR - Medicine overview

English (EN) (79.42 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 07/08/2018

[View](/en/documents/overview/samsca-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-289)

български (BG) (106.05 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/bg/documents/overview/samsca-epar-medicine-overview_bg.pdf)

español (ES) (79.21 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/es/documents/overview/samsca-epar-medicine-overview_es.pdf)

čeština (CS) (103.8 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/cs/documents/overview/samsca-epar-medicine-overview_cs.pdf)

dansk (DA) (78.63 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/da/documents/overview/samsca-epar-medicine-overview_da.pdf)

Deutsch (DE) (79.95 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/de/documents/overview/samsca-epar-medicine-overview_de.pdf)

eesti keel (ET) (78.13 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/et/documents/overview/samsca-epar-medicine-overview_et.pdf)

ελληνικά (EL) (111.62 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/el/documents/overview/samsca-epar-medicine-overview_el.pdf)

français (FR) (79.84 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/fr/documents/overview/samsca-epar-medicine-overview_fr.pdf)

hrvatski (HR) (99.71 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/hr/documents/overview/samsca-epar-medicine-overview_hr.pdf)

italiano (IT) (78.46 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/it/documents/overview/samsca-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (108.05 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/lv/documents/overview/samsca-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (102.38 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/lt/documents/overview/samsca-epar-medicine-overview_lt.pdf)

magyar (HU) (99.04 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/hu/documents/overview/samsca-epar-medicine-overview_hu.pdf)

Malti (MT) (104.16 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/mt/documents/overview/samsca-epar-medicine-overview_mt.pdf)

Nederlands (NL) (79.08 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/nl/documents/overview/samsca-epar-medicine-overview_nl.pdf)

polski (PL) (102.38 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/pl/documents/overview/samsca-epar-medicine-overview_pl.pdf)

português (PT) (78.69 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/pt/documents/overview/samsca-epar-medicine-overview_pt.pdf)

română (RO) (100.88 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/ro/documents/overview/samsca-epar-medicine-overview_ro.pdf)

slovenčina (SK) (102.99 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/sk/documents/overview/samsca-epar-medicine-overview_sk.pdf)

slovenščina (SL) (98.04 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/sl/documents/overview/samsca-epar-medicine-overview_sl.pdf)

Suomi (FI) (78.34 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/fi/documents/overview/samsca-epar-medicine-overview_fi.pdf)

svenska (SV) (78.43 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

07/08/2018

[View](/sv/documents/overview/samsca-epar-medicine-overview_sv.pdf)

## Product information

Samsca : EPAR - Product Information

English (EN) (379.55 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 26/03/2025

[View](/en/documents/product-information/samsca-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-230)

български (BG) (449.22 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/bg/documents/product-information/samsca-epar-product-information_bg.pdf)

español (ES) (376.96 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/es/documents/product-information/samsca-epar-product-information_es.pdf)

čeština (CS) (439.76 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/cs/documents/product-information/samsca-epar-product-information_cs.pdf)

dansk (DA) (423.12 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/da/documents/product-information/samsca-epar-product-information_da.pdf)

Deutsch (DE) (401.05 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/de/documents/product-information/samsca-epar-product-information_de.pdf)

eesti keel (ET) (375.91 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/et/documents/product-information/samsca-epar-product-information_et.pdf)

ελληνικά (EL) (423.32 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/el/documents/product-information/samsca-epar-product-information_el.pdf)

français (FR) (395.78 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/fr/documents/product-information/samsca-epar-product-information_fr.pdf)

hrvatski (HR) (418.71 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/hr/documents/product-information/samsca-epar-product-information_hr.pdf)

íslenska (IS) (374.87 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/is/documents/product-information/samsca-epar-product-information_is.pdf)

italiano (IT) (387.43 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/it/documents/product-information/samsca-epar-product-information_it.pdf)

latviešu valoda (LV) (428.26 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/lv/documents/product-information/samsca-epar-product-information_lv.pdf)

lietuvių kalba (LT) (417.54 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/lt/documents/product-information/samsca-epar-product-information_lt.pdf)

magyar (HU) (455.14 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/hu/documents/product-information/samsca-epar-product-information_hu.pdf)

Malti (MT) (472.83 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/mt/documents/product-information/samsca-epar-product-information_mt.pdf)

Nederlands (NL) (388.88 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/nl/documents/product-information/samsca-epar-product-information_nl.pdf)

norsk (NO) (383.79 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/no/documents/product-information/samsca-epar-product-information_no.pdf)

polski (PL) (439.26 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/pl/documents/product-information/samsca-epar-product-information_pl.pdf)

português (PT) (446.44 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/pt/documents/product-information/samsca-epar-product-information_pt.pdf)

română (RO) (427.5 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/ro/documents/product-information/samsca-epar-product-information_ro.pdf)

slovenčina (SK) (484.68 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/sk/documents/product-information/samsca-epar-product-information_sk.pdf)

slovenščina (SL) (423.24 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/sl/documents/product-information/samsca-epar-product-information_sl.pdf)

Suomi (FI) (422.61 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/fi/documents/product-information/samsca-epar-product-information_fi.pdf)

svenska (SV) (380.84 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

26/03/2025

[View](/sv/documents/product-information/samsca-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0051 13/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Samsca : EPAR - All Authorised presentations

English (EN) (28.57 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 28/01/2020

[View](/en/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-396)

български (BG) (55.81 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/bg/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.78 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/es/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.46 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/cs/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.01 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/da/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.49 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/de/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (30.15 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/et/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.23 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/el/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_el.pdf)

français (FR) (29.54 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/fr/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.52 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/hr/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.05 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/is/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.54 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/it/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.14 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/lv/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.49 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/lt/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.93 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/hu/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (46.05 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/mt/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.89 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/nl/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (28.36 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/no/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.65 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/pl/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.62 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/pt/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.12 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/ro/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.22 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/sk/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (36.15 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/sl/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.79 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/fi/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.43 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

28/01/2020

[View](/sv/documents/all-authorised-presentations/samsca-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Samsca Active substance tolvaptan International non-proprietary name (INN) or common name tolvaptan Therapeutic area (MeSH) Inappropriate ADH Syndrome Anatomical therapeutic chemical (ATC) code C03XA01

### Pharmacotherapeutic group

Diuretics

### Therapeutic indication

Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).

## Authorisation details

EMA product number EMEA/H/C/000980 Marketing authorisation holder

Otsuka Pharmaceutical Netherlands B.V.

Herikerbergweg 292

Opinion adopted 28/05/2009 Marketing authorisation issued 02/08/2009 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Samsca : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (225.69 KB - PDF)

**First published:** 09/11/2010

**Last updated:** 26/03/2025

[View](/en/documents/procedural-steps-after/samsca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Samsca-H-C-980-P46-022 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/304438/2018

English (EN) (227.61 KB - PDF)

**First published:** 24/05/2018

**Last updated:** 24/05/2018

[View](/en/documents/variation-report/samsca-h-c-980-p46-022-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Samsca : EPAR - Public assessment report

English (EN) (1.16 MB - PDF)

**First published:** 18/08/2009

**Last updated:** 18/08/2009

[View](/en/documents/assessment-report/samsca-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for  Samsca

Reference Number: EMEA/CHMP/285157/2009

English (EN) (75.66 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-samsca_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/03/2025

## Share this page

[Back to top](#main-content)